The objective of this study is to compare pharmacokinetics after single oral administration of candesartan and rosuvastatin each separately versus coadministration of candesartan and rosuvastatin in healthy male volunteers.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Chungnam National University Hospital
Jung-gu, Daejeon, South Korea
AUCτ,ss of candesartan
0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h
Time frame: 22 points
Cmax,ss of candesartan
0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h
Time frame: 22 points
AUCτ,ss of rosuvastatin
0(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h
Time frame: 28 points
Cmax,ss of rosuvastatin
0(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h
Time frame: 28 points
tmax,ss of candesartan
0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h
Time frame: 22 points
CLss/F of candesartan
0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h
Time frame: 22 points
Cmin,ss of candesartan
0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h
Time frame: 22 points
tmax,ss of rosuvastatin
0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h
Time frame: 28 points
CLss/F of rosuvastatin
0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 28 points
Cmin,ss of rosuvastatin
0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h
Time frame: 28 points